The case can be assigned as an opening vignette, during the initial phases of business strategy, since the case situations and concepts are both simple and clear. It can also be assigned for an in‐depth treatment of manufacturing strategy.Case overview – The case focuses on Capital Mills ...
The clinical manifestations of CML are insidious, changing somewhat as the disease progresses through its 3 phases (chronic, accelerated, and blast). Patients in the chronic phase may be asymptomatic or may display any of the following signs and symptoms: Fatigue, weight loss, loss of energy, ...
Major cytogenetic response: Presence of Ph+ cells in 0%-35% metaphases Minor cytogenetic response: Ph+ >35% metaphases Molecular response Molecular response is monitored by quantitative polymerase chain reaction (qPCR) studies on peripheral blood. It is usually performed at diagnosis, then every...
Expression pattern of microRNAs associated with CML phases and their disease related targets. Mol Cancer 2011; 10: 41–54. Article CAS Google Scholar Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with...
we’ll get to that discussion. But let’s not forget about the patients who present in advance phases, like accelerated or even blast crisis. There my feeling is that the second-generation drugs are, I believe, superior to imatinib. That is my personal belief. I’d love to hear what yo...
Chronic myeloid leukaemia can be quite variable in terms of its natural history. The relatively stable chronic phase of this leukaemia averages approximately 4 years. Having said that, some patients have had prolonged chronic phases of more than 15 years, although this is much less common. ...
(n=76), respectively.1 Hematologic resistance—defined as the failure to achieve a hematologic response—was associated with BCR-ABL mutations in 45% of patients in all phases.1 随着治疗时间的增加,伊马替尼耐药增加1 * 二代TKI之间比较,达沙替尼与尼洛替尼对T315I突变均表现出无效(题外话:如合用...
In advanced phases of CML in adult patients, intensive conditioning is generally recommended as offering the best chance of leukemia-free survival [36, 66]. To mitigate transplant-related toxicity, reduced-intensity conditioning (RIC) is a possible alternative. In pediatric patients, experience with ...
Complete or partial cytogenetic response, which they defined respectively as 0% and 1% to 35% metaphases, respectively. Major cytogenetic response, the sum of complete and partial responses. Major molecular response, or more than 3 log reductions of BCR-ABL transcript levels from the standardized ...
However, in 1998 the introduction of imatinib, the first tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 oncoprotein, has fundamentally altered treatment strategies for patients in all phases of CML. Imatinib is now recommended as initial treatment for all patients who present...